New Advances in Lung Cancer Treatment: Four Innovative Targeted Drugs from China and Their Mechanisms of Action

In recent years, with the rapid development of precision medicine, lung cancer treatment has been gradually shifting from traditional chemotherapy toward targeted therapy and immunotherapy. By focusing on specific genetic mutations or signaling pathways in tumor cells, targeted drugs can more precisely inhibit tumor growth while minimizing damage to normal cells.

Against this backdrop, innovative anticancer drugs developed in China are increasingly gaining global attention. Among them, Sosimerasib Sulfate Tablets, Mifanertinib Maleate Tablets, Furmonertinib, and Dirozalkib Tablets represent emerging targeted therapies that may offer new treatment options for certain patients with lung cancer.

What Is Targeted Therapy and Why Is It Important for Lung Cancer?

Targeted therapy is a treatment approach designed to act on specific molecular targets within cancer cells. Many lung cancer patients carry particular genetic mutations in their tumor cells, such as:

● EGFR mutations

● ALK fusions

● ROS1 fusions

● KRAS mutations

Targeted drugs directly interfere with these abnormal signaling pathways, thereby blocking tumor cell growth and spread.

Compared with conventional chemotherapy, targeted therapy often offers several advantages:

● More precise action on tumor cells

● Relatively manageable side effects

● Longer-lasting responses in some patients

For these reasons, targeted therapy has become an essential component in the treatment of non-small cell lung cancer (NSCLC).

1️⃣Sosimerasib Sulfate Tablets: A New Direction in Targeted Lung Cancer Research

Sosimerasib Sulfate Tablets are a small-molecule targeted drug that has been drawing attention in lung cancer research.

Mechanism of action:

This drug works by inhibiting key tyrosine kinase activities involved in tumor cell signaling. By blocking these growth signals, it may slow down tumor cell proliferation.Research characteristics:

● Oral small-molecule targeted therapy

● Designed to target specific oncogenic signaling pathways

● Potential value in precision lung cancer treatment research

As clinical studies continue to advance, this type of targeted therapy may provide additional treatment possibilities for certain patient populations.

2️⃣Mifanertinib Maleate Tablets: A New Option for EGFR-Targeted Therapy

Mifanertinib Maleate Tablets are an EGFR tyrosine kinase inhibitor (EGFR-TKI) developed for patients with EGFR-mutated non-small cell lung cancer.

Mechanism of action:

Mutations in the EGFR gene cause tumor cells to continuously send growth signals. Mifanertinib blocks the EGFR signaling pathway, thereby inhibiting tumor cell proliferation and promoting apoptosis.Clinical significance:

● Designed for patients with EGFR-mutated lung cancer

● Potential to be combined with other treatment strategies

● Reflects ongoing progress in EGFR-targeted drug development in China

EGFR-targeted therapy has become one of the most important pillars of precision medicine for lung cancer worldwide.

3️⃣Furmonertinib: An Important Advance in Third-Generation EGFR Targeted Therapy

Furmonertinib is a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) independently developed in China for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

Mechanism of action:

Furmonertinib selectively binds to the mutant EGFR kinase domain, blocking downstream signaling pathways such as EGFR-MAPK and PI3K-AKT. This prevents tumor cells from continuously growing and dividing.

Clinical features:

● Effective against the EGFR T790M resistance mutation

● Can be used in first-line or later-line treatment of EGFR-mutated NSCLC

● Shows a degree of central nervous system penetration, which may benefit patients with brain metastases

With the advancement of precision oncology, next-generation targeted drugs such as Furmonertinib are helping to improve treatment outcomes and expand therapeutic options for patients with EGFR-mutated lung cancer.

4️⃣Dirozalkib Tablets: Exploring New Small-Molecule Targeted Therapies

Dirozalkib Tablets are a novel small-molecule targeted drug that has attracted increasing interest in oncology research.

Mechanism of action:

● Inhibits tumor-related signaling pathways

● Interferes with the tumor microenvironment

● Blocks tumor cell proliferation

Through these mechanisms, the drug may help slow tumor progression.

Research significance:

The development of new small-molecule targeted drugs continues to expand the possibilities for lung cancer treatment.

The Global Impact of China’s Innovative Anticancer Drugs

Over the past decade, China’s pharmaceutical R&D capabilities have grown significantly, leading to breakthroughs in several oncology fields, including:

● Targeted therapies

● PD-1 immunotherapy

● CAR-T cell therapy

● Antibody–drug conjugates (ADC)

An increasing number of innovative Chinese drugs are entering international clinical trials or overseas markets, providing more treatment choices for patients worldwide.

From the perspective of the global pharmaceutical industry, organizations involved in international drug supply chains—such as Dengyue Pharma—also closely follow these emerging therapies. By monitoring global drug development trends, they help healthcare institutions and industry professionals stay informed about the latest advances in innovative medicines.

Conclusion

With the rapid development of precision medicine, targeted therapy is transforming the treatment landscape of lung cancer. Emerging drugs such as Sosimerasib Sulfate, Mifanertinib Maleate, Furmonertinib, and Dirozalkib represent the ongoing progress of innovative therapies developed in China.

For patients, staying informed about new treatment developments, communicating closely with healthcare professionals, and selecting therapies based on individual genetic profiles remain essential strategies in managing lung cancer.